Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Clinuvel Progresses Innovative DNA Repair Program
Details : Having commercialised SCENESSE® in Europe and the USA for the rare genetic disorder porphyria (EPP), CLINUVEL is expanding its clinical research, aiming to confirm how intervention with the drug enhances elimination of photoproducts and regeneration of ...
Product Name : Scenesse
Product Type : Peptide
Upfront Cash : Inapplicable
October 09, 2020
Lead Product(s) : Afamelanotide
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable